BeiGene, Ltd.
BGNE US07725L1026
Cayman Islands KY1-1108
Camana Bay C/O Mourant Ozannes Corporate Services (Cayman) Limited
94 Solaris Avenue
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Annual Performance 1
| 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 56% | 4% | -18% | -20% | -0% |
Historical Performance 1
| 1M | 3M | 6M | 1Y | 3Y | 5Y | All Time |
|---|---|---|---|---|---|---|
| -28% | 17% | 7% | -22% | -17% | 152% | 523% |
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Transactions: 28 Insiders: 1
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Wang Xiaodong |
183.60 USD |
2,600 Sold |
477,369 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
194.01 USD |
725 Sold |
140,655 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
184.83 USD |
7,063 Sold |
1,305,473 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
192.61 USD |
1,374 Sold |
264,641 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
188.79 USD |
1,300 Sold |
245,428 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
186.99 USD |
9,266 Sold |
1,732,647 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
195.67 USD |
300 Sold |
58,700 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
191.78 USD |
993 Sold |
190,435 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
190.57 USD |
1,833 Sold |
349,312 USD |
10/12/2024 | 10/12/2024 |
| Wang Xiaodong |
187.60 USD |
6,350 Sold |
1,191,280 USD |
10/12/2024 | 10/12/2024 |